Showing results (571-580 of 628) with videos related to

Sort By:
Pageof 63
Oncoimmunology|May 1, 2023
Increased tryptophan, but not increased glucose metabolism, predict resistance of pembrolizumab in stage III/IV melanomaJorge D Oldan, Benjamin C Giglio, Eric Smith, et al.
JAMA Dermatology|August 28, 2014
Comparison of clinicopathologic features and survival of histopathologically amelanotic and pigmented melanomas: a population-based studyNancy E Thomas, Anne Kricker, Weston T Waxweiler, et al.
Cell Genomics|August 14, 2024
Genetic and functional analysis of Raynaud's syndrome implicates loci in vasculature and immunityAnniina Tervi, Markus Ramste, Erik Abner, et al.
Cancers|July 29, 2025
Real World Outcomes of Patients with Aggressive Lymphoma and Autoimmune Disease Treated with CARTNicole J Altomare, Megan M Herr, Nisha M Nair, et al.
Journal of Hematology & Oncology|November 10, 2023
Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort studyNarendranath Epperla, Lei Feng, Nirav N Shah, et al.
Melanoma Research|March 4, 2021
Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activity (NCI9922)Stergios J Moschos, Zeynep Eroglu, Nikhil I Khushalani, et al.
Nature Communications|February 7, 2024
Overlay databank unlocks data-driven analyses of biomolecules for allAnne M Kiirikki, Hanne S Antila, Lara S Bort, et al.
JAMA Oncology|July 7, 2015
Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary MelanomaNancy E Thomas, Sharon N Edmiston, Audrey Alexander, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2015
IL2 Inducible T-cell Kinase, a Novel Therapeutic Target in MelanomaCraig C Carson, Stergios J Moschos, Sharon N Edmiston, et al.
Blood Advances|March 26, 2024
Impact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapyReem Karmali, Rushad Machhi, Narendranath Epperla, et al.
Pageof 63